Kcnn4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNN4 (SK4, IK1) is a calcium-activated potassium channel important for erythrocyte volume regulation and immune cell activation. It is also expressed in the brain where it contributes to glial function.
KCNN4 (Potassium Calcium-Activated Channel Subfamily N Member 4) is a gene located on chromosome 19q13 that plays an important role in neurodegenerative disease. Mutations in KCNN4 are associated with Erythrocyte Disorders, Immune Activation. The gene is catalogued as NCBI Gene ID 3782 and OMIM 604270.
The KCNN4 gene encodes a protein involved in key neuronal functions. It is expressed in Erythrocytes, Immune cells, Salivary glands.
- Erythrocytes, Immune cells, Salivary glands
Expression data is available from the Allen Human Brain Atlas.
KCNN4 mutations are linked to the following conditions:
Erythrocyte Disorders, Immune Activation
The study of Kcnn4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Potassium channels in neurons: Hille B. Ionic Channels of Excitable Membranes. 3rd ed. Sinauer Associates; 2001.
- KCNN channels (SK/IK): Stocker M. Nat Rev Neurosci. 2004;5(10):758-770. PMID:15378036
- KCa channels in neurodegeneration: Shah NH, et al. Nat Rev Neurosci. 2018;19(9):485-498. PMID:30046008
- Potassium channel dysfunction in AD: Angulo E, et al. J Neurosci. 2004;24(20):4676-4682. PMID:15140932
- Potassium channels and neuronal excitability: Bean BP. Nat Rev Neurosci. 2007;8(6):451-465. PMID:17541432
- SK channel activators as therapy: Ehling P, et al. Nat Rev Drug Discov. 2020;19(11):773-789. PMID:32877965
- Potassium channels in PD: Lüscher C, Slesinger PA. Nat Rev Neurosci. 2010;11(9):569-579. PMID:20649637
- Ion channel therapeutics: Garnock-Jones KP. CNS Drugs. 2017;31(5):383-392. PMID:28447065
- Stocker M. Calcium-activated potassium channels: molecular diversity and function. Physiological Reviews. 2004;84(3):903-934. PMID:15269336
- Bhattacharjee A, Kaczmarek LK. Slack channels: from genes to function. Cell Calcium. 2005;38(3-4):237-246. PMID:16102830
- Passmore GM, Reilly JM, Wang Z, et al. Functional analysis of KCa3.1 channel blockers in sensory neurons. European Journal of Pharmacology. 2012;691:28-36. PMID:22705073
- Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery. 2009;8(12):982-1001. PMID:19960002
- Kohler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273(5282):1709-1714. PMID:8781166
- Herson PS, Brody DL, Kaczmarek LK. In quest of the cardiac sK channel. Cardiovascular Research. 1999;42(2):377-385. PMID:10510335
- Mathie A, Wooltorton JR, Watkins CS. Voltage-gated potassium channels as therapeutic targets. CNS Drugs. 1998;9(5):335-346.
- Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends in Neurosciences. 2001;24(9):517-526. PMID:11530637